Out Of Stealth, Artax Hopes To Pioneer Nck Targeting In Autoimmune Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
$10 million Series B will enable lead candidate AX-024 to advance into Phase IIa in undetermined autoimmune indications.